Oncolytics Biotech Inc. Enters into Sponsorship Agreement with NCIC CTG for Randomized Phase II Study in Non-Small Cell Lung Cancer
Oncolytics Biotech Inc. ((NASDAQ: ONCY) announced today that it has entered into an agreement whereby the NCIC Clinical Trials Group at Queen's University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN in patients with advanced or metastatic non-small cell lung cancer.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.